Business context and reporting period
EyePoint Pharmaceuticals, Inc. filed this Form 10-K for the fiscal year ended December 31, 2020; it is an annual report, not a standalone fourth-quarter report. The company develops and commercializes ophthalmic drugs using sustained-delivery technologies. Its marketed products are YUTIQ, for chronic non-infectious posterior uveitis, and DEXYCU, for post-operative ocular inflammation. Its lead candidate, EYP-1901, was entering Phase 1 development for wet age-related macular degeneration (AMD); YUTIQ50 remained in development.
Key financial metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Total revenue | $34.4 million | $20.4 million |
| Product sales, net | $20.8 million | $16.8 million |
| Operating loss | $37.3 million | $47.9 million |
| Net loss | $45.4 million | $56.8 million |
| Cash used in operating activities | $14.4 million | $56.7 million |
| Cash and cash equivalents at year-end | $44.9 million | $22.2 million |
- Product sales comprised $13.9 million of YUTIQ and $7.0 million of DEXYCU revenue in 2020. The filing does not provide a clear gross-margin figure.
- Operating expenses were $71.7 million, including $17.4 million in R&D, $25.3 million in sales and marketing, and $20.7 million in general and administrative costs.
- Year-end total assets were $91.7 million, total liabilities $73.2 million, and stockholders’ equity $18.5 million. Long-term debt on the balance sheet was $38.0 million; the company reported approximately $40.5 million of CRG loan obligations, including interest and exit fee. The CRG loan carries 12.5% annual interest and matures December 31, 2023.
- Cash used in investing activities was $0.4 million; financing activities provided $37.5 million. The company received approximately $108 million net from a February 2021 share offering.
Material changes versus the prior comparable period
- Total revenue rose 69%, mainly because license and collaboration revenue increased to $11.9 million from $1.4 million. This included $9.5 million from an Ocumension agreement and approximately $2.0 million for the DEXYCU license in China.
- Net product sales increased 24% despite pandemic-related disruption. Sales and marketing expense fell 15% following commercial restructuring, while R&D rose 13% and general and administrative expense rose 16%.
- Net loss narrowed by $11.4 million. Operating cash use declined substantially, with the year-over-year change reflecting working-capital movements, including increased deferred revenue.
- The company sold future Alimera royalties for $16.5 million in December 2020 and applied $15.0 million to CRG debt. The proceeds were recorded as deferred revenue, rather than recognized entirely as current-period revenue; future Alimera royalty income to EyePoint is expected to decline.
Outlook, commentary, risks and unusual items
- Management expected cash and cash equivalents at year-end, the February 2021 offering proceeds, and anticipated product-sale cash inflows to fund its operating plan through the second quarter of 2022, assuming planned EYP-1901 trial timing and other expectations. The filing cautions that actual cash needs and product demand may differ.
- EyePoint expected initial EYP-1901 Phase 1 data in the second half of 2021. The trial was planned for 13 wet AMD patients, with safety as the primary endpoint. YUTIQ50’s trial timing and investment requirements remained under evaluation.
- COVID-19 reduced physician visits and elective cataract surgeries, harming YUTIQ and DEXYCU demand. Customer demand improved sequentially in the third and fourth quarters; fourth-quarter demand was reported up 10% quarter over quarter for YUTIQ and 30% for DEXYCU. The duration of pandemic effects remained uncertain.
- The SEC Enforcement Division subpoenaed the company in May 2020 regarding product sales and demand, revenue recognition, projections, and related reporting and compliance. EyePoint said it was cooperating and had not identified GAAP-inconsistent revenue-recognition items in procedures performed to date; it could not predict the investigation’s duration, scope, or outcome.
- CRG waived the 2020 product-revenue covenant and reduced the 2021 covenant from $80 million to $45 million. The company warned it might still fail to meet the 2021 covenant; a default could permit acceleration and enforcement against collateral. DEXYCU’s Medicare pass-through reimbursement was scheduled to expire in March 2022, potentially affecting separate payment.
- The $2.0 million PPP loan forgiveness application was pending. The company also disclosed significant cumulative losses, future financing needs, product commercialization and reimbursement risks, clinical-development uncertainty, and reliance on third-party manufacturers and collaborators.
- 2020 included a $0.9 million debt-extinguishment loss from partial CRG prepayment and a $0.9 million write-down of out-of-specification DEXYCU batches. The company completed a 1-for-10 reverse stock split and issued shares through public, ATM, and Ocumension financings.
Most important facts for investors to verify
- Progress and safety results from EYP-1901’s Phase 1 trial, and whether pandemic or enrollment issues affect timing.
- Whether YUTIQ and DEXYCU demand and net sales recover sufficiently to support commercialization and meet CRG covenants, including the $45 million 2021 threshold.
- Cash burn, the assumptions behind management’s stated runway, and financing needs after the February 2021 offering.
- The outcome and potential financial, operational, or disclosure consequences of the SEC investigation; also verify the status of PPP loan forgiveness.
- DEXYCU reimbursement after its pass-through period ends, product-return and chargeback estimates, and the effect of customer concentration: three customers accounted for 90% of 2020 revenue.
- CRG debt service, covenant compliance, and the effect of future equity issuance and dilution, including Ocumension’s participation rights.